Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
暂无分享,去创建一个
P. Gaulard | B. Coiffier | H. Tilly | C. Gisselbrecht | G. Delsol | C. Haioun | P. Morel | M. Fournier | O. Hermine | J. Gabarre | J. Brière | D. Sibon | L. Lamant | A. Sonet | S. Bologna
[1] Uma Yasothan,et al. Brentuximab vedotin , 2022, Nature Reviews Drug Discovery.
[2] R. Advani,et al. Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update , 2011 .
[3] A. Younes,et al. Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.
[4] E. Grande,et al. Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment , 2011, Molecular Cancer Therapeutics.
[5] J. Delabie,et al. Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01) , 2010 .
[6] A. Rosenwald,et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2010, Blood.
[7] John P Leonard,et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.
[8] T. Molina,et al. Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low–intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol , 2010, Leukemia & lymphoma.
[9] B. Coiffier,et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] G. Brittinger,et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. , 2009, Blood.
[11] M. Djokic. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project , 2009 .
[12] C. Volteau,et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Delsol,et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. , 2008, Blood.
[14] P. Gaulard,et al. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] T. Molina,et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Loehrer,et al. International Staging System for Multiple Myeloma , 2006 .
[17] T. Molina,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.
[18] E. Iannitto,et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.
[19] T. Molina,et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.
[20] F. Cabanillas,et al. Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] T. Molina,et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Gaulard,et al. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. , 2001, The hematology journal : the official journal of the European Haematology Association.
[23] M. Seto,et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. , 2000, Blood.
[24] P. Gaulard,et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Deconinck,et al. Autologous stem cell transplantation for anaplastic large‐cell lymphomas: results of a prospective trial , 2000, British journal of haematology.
[26] B. Coiffier,et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Coiffier,et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] T. Greiner,et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. , 1999, Blood.
[29] D. de Jong,et al. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. , 1999, Blood.
[30] S. Pileri,et al. ALK+ lymphoma: clinico-pathological findings and outcome. , 1999, Blood.
[31] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Rossi,et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[34] P. Gaulard,et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. , 1997, Blood.
[35] J. Blay,et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Hallek,et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.
[37] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[38] B. Coiffier,et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.
[39] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[40] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[41] D.,et al. Regression Models and Life-Tables , 2022 .